Status:
COMPLETED
Sevelamer Hydrochloride in Peritoneal Dialysis Patients
Lead Sponsor:
The University of Hong Kong
Conditions:
Endstage Renal Disease
Eligibility:
All Genders
25-80 years
Phase:
NA
Brief Summary
To test the hypothesis that second-line fixed low-dose sevelamer hydrochloride therapy is as effective as first-line high-dose sevelamer hydrochloride therapy in limiting the progression of cardiovasc...
Detailed Description
Cardiovascular disease accounts for nearly 50% of the mortality and is the most frequent cause of hospitalization in ESRD patients. Hyperphosphatemia is increasingly recognized to be an important pred...
Eligibility Criteria
Inclusion
- ESRD patients receiving long-term peritoneal dialysis treatment with hyperphosphatemia currently receiving aluminum-based phosphorus binders or whose phosphorus control remains suboptimal with calcium-based binders only
- Patients who cannot afford to self-pay sevelamer hydrochloride.
- Patients who provided informed consent for the study
Exclusion
- Patients with underlying active malignancy
- Patients with cyanotic congenital heart disease
- Patients with poor general condition
- Patients with plan for living related kidney transplant within coming 1 year
- Female patients with pregnancy
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00745589
Start Date
July 1 2008
End Date
January 1 2015
Last Update
June 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Mary Hospital, Tung Wah Hospital
Hong Kong, Hong Kong, 0000